Phase 3 RCT in 698 patients with intermediate-risk prostate cancer: SBRT vs moderately hypofractionated IMRT showed no difference in 2-year urinary decline (35.4% vs 33.7%), fewer bowel declines (34.9% vs 43.8%), and was not superior for 3-year DFS (88.6% vs 92.1%).
RCTn = 698
Ellis et al. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial